The viscosupplementation market offers a range of benefits for patients with osteoarthritis and related joint conditions, including pain relief, improved joint mobility, and reduced inflammation. The dominating segment in this market is the three-injection viscosupplements, which are gaining popularity due to their efficacy and convenience. As more governments approve these treatments, their positive impact on patient's lives becomes increasingly evident, driving growth in this segment and underscoring the importance of accessible and effective joint care solutions.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/europe-viscosupplementation-market
Data Bridge Market Research analyses that the Europe Viscosupplementation Market was valued at USD 443.58 million in 2022 and is expected to reach the value of USD 821.05 million by 2030, at a CAGR of 8.0% during the forecast period of 2023-2030. Patients prefer non-surgical approaches for managing joint pain, driving the increased use of viscosupplements. These treatments offer a less invasive option, providing relief from joint discomfort without the need for surgery, and aligning with patient preferences for more conservative and effective pain management solutions.
Key Findings of the Study
The aging population is expected to drive the market's growth rate
The expanding elderly population is particularly vulnerable to joint-related conditions such as osteoarthritis, which often lead to pain and reduced mobility. As this demographic continues to grow, so does the demand for effective treatments such as viscosupplements. These products provide a non-invasive way to alleviate joint pain and enhance joint function, making them increasingly attractive to older individuals seeking to maintain an active and pain-free lifestyle as they age. This demographic trend fuels the rising demand for viscosupplements in the healthcare market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Source (Non-Animal Origin and Animal Origin), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight, and High Molecular Weight), Injection (Single Injection, Three Injection, and Five Injection), Age Group (Geriatric and Adult), End User (Hospitals, Orthopedic Clinics, Ambulatory Care Center, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Anika Therapeutics, Inc. (U.S.), SEIKAGAKU CORPORATION (Japan), Bioventus (U.S.), Fidia Farmaceutici S.p.A (Italy), Ferring B.V (Netherlands), Sanofi-Aventis U.S. LLC (U.S.), Zimmer Biomet (U.S.), APTISSEN (France), Johnson & Johnson Services, Inc. (U.S.), LG Chem (South Korea), Viatris Inc. (U.S.), IBSA Institut Biochimique SA (Switzerland), TRB CHEMEDICA SA (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe viscosupplementation market is segmented into source, age group, molecular weight, injection, end user, and distribution channel.
- On the basis of source, the Europe viscosupplementation market is segmented into animal origin and non-animal origin.
- On the basis of molecular weight, the Europe viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.
- On the basis of injection, the Europe viscosupplementation market is segmented into single injection, three injection, and five injection.
- On the basis of age group, the Europe viscosupplementation market is segmented into geriatric and adult.
- On the basis of end user, the Europe viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care center, and others.
- On the basis of distribution channel, the Europe viscosupplementation market is segmented into direct tender and retail sales.
Major Players
Data Bridge Market Research recognizes the following companies as the Europe viscosupplementation market players in Europe viscosupplementation market are Anika Therapeutics, Inc. (U.S.), SEIKAGAKU CORPORATION (Japan), Bioventus (U.S.), Fidia Farmaceutici S.p.A (Italy), Ferring B.V (Netherlands), Sanofi-Aventis U.S. LLC (U.S.), Zimmer Biomet (U.S.), APTISSEN (France), Johnson & Johnson Services, Inc. (U.S.), LG Chem (South Korea), Viatris Inc. (U.S.).
Market Developments
- In May 2022, Fidia Farmaceutici S.p.A. introduced its innovative portfolio harnessing the regenerative properties of hyaluronic acid in Spain. At the 20th Aesthetic & Anti-aging Medicine World Congress 2022 in Monte Carlo, the company presented its Aesthetic Care portfolio, highlighting its groundbreaking ACP (Auto-Crosslinked Polymer) technology. Fidia Farmaceutici S.p.A. successfully launched its comprehensive Hyal System and Hy-Tissue portfolio in Spain, emphasizing its commitment to advancing research and applications related to hyaluronic acid.
- In August 2021, SEIKAGAKU CORPORATION unveiled the introduction of HyLink, a single-injection viscosupplement designed for treating knee osteoarthritis in Taiwan. The launch was facilitated through a partnership with TCM Biotech International Corp. HyLink features a cross-linked hyaluronate hydrogel as its primary component, produced using Seikagaku's distinctive cross-linking technology. This expansion of its product portfolio marks a significant milestone for the company in broadening its offerings for osteoarthritis treatment.
Regional Analysis
Geographically, the countries covered in the Europe viscosupplementation market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
As per Data Bridge Market Research analysis:
Germany is the dominant region Europe viscosupplementation market during the forecast period 2023 - 2030
Germany is set to lead the European viscosupplementation market due to the rising preference for shorter treatment regimens despite higher costs. The growing incidence of target ailments such as osteoarthritis and increasing government approvals for three-injection viscosupplements are anticipated to fuel segment growth. These factors underscore a shift towards more efficient and effective treatment options, positioning Germany as a dominant player in the European viscosupplementation market.
For more detailed information about the Europe viscosupplementation market report, click here – https://www.databridgemarketresearch.com/de/reports/europe-viscosupplementation-market
